MEM-288
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1Active
Key Facts
Indication
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase
Phase 1
Status
Active
Company
About Memgen
Memgen is a private, clinical-stage biotech developing a proprietary viral immunotherapy platform for oncology. Its lead candidate, MEM-288, is an oncolytic adenovirus engineered to express CD40 ligand and interferon-beta (IFNβ), designed to prime a potent, tumor-targeted T-cell response. Preliminary Phase 1 data in advanced NSCLC shows promising clinical benefit and immune activation with a favorable safety profile. The company is led by a seasoned management team with strong scientific and financial expertise, supported by a distinguished scientific advisory board.
View full company profile